ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
암 유전자 억제제 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안의 성장은 의료 투자 증가, 암에 상관없는 치료의 강조, 표적 치료의 사용 증가, 지원적인 규제 및 상환 체계, 맞춤형 의약품 및 동반 진단의 발전에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 차세대 KRAS 억제제의 출현, AI 기반 의약품 발견 플랫폼, 실시간 액체 생검의 통합, 암 미세 환경의 조절, 표적 나노 입자 기반 의약품 전달 시스템의 개발 등이 있습니다.
암의 유병률 증가는 앞으로 암 유전자 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 암은 신체에서 비정상적인 세포가 통제되지 않고 증식 및 확산되는 것을 특징으로 하는 질병을 의미합니다. 흡연, 불량한 식습관, 운동 부족, 알코올 섭취와 같은 습관이 신체를 약화시키고 암세포의 성장을 촉진하기 때문에 암은 증가하고 있습니다. 암 유전자 억제제는 암세포의 성장을 촉진하는 특정 유전자를 표적으로 차단하여 암의 발생 및 진행을 늦추거나 막아 암과 싸우는 데 도움이 됩니다. 예를 들어, 2024년 7월에 영국 기반 자선 단체인 Cancer Research UK가 발표한 보고서에 따르면, 영국에서 2023-2025년 약 20,800건이었던 새로운 흑색종 피부암 사례의 연간 평균 수는 2038-2040년 약 26,500건으로 증가할 것으로 예상됩니다.
암 유전자 억제제 시장에서 활동하는 주요 기업들은 암 치료의 정확성과 효능을 높이기 위해 새로운 기능적 유전체학 접근법과 같은 혁신적인 치료 옵션 개발에 주력하고 있습니다. 새로운 기능적 유전체학 접근법은 다양한 유전체, 전사체 및 후성 유전체 데이터를 통합하여 유전자의 기능과 암과 같은 질병에서 그 역할을 이해하기 위한 첨단 방법론을 의미합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 암 유전자 억제제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 암 유전자 억제제 시장 : 성장률 분석
세계의 암 유전자 억제제 시장 실적 : 규모와 성장(2019-2024년)
세계의 암 유전자 억제제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 암 유전자 억제제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 암 유전자 억제제 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사
세계의 암 유전자 억제제 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
저분자 의약품
생물학적 제제
병용 요법
세계의 암 유전자 억제제 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
유방암
난소암
폐암
췌장암
기타 적응증
세계의 암 유전자 억제제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 암 유전자 억제제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
기타 최종 사용자
세계의 암 유전자 억제제 시장 : 경구 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
저분자 억제제
표적 치료제
티로신 키나아제 억제제(TKI)
세계의 암 유전자 억제제 시장 : 주사 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체(MAbs)
펩티드 수용체 방사성 리간드 요법(PRRT)
소분자 억제제(주사제)
유전자 치료 주사
제7장 지역별, 국가별 분석
세계의 암 유전자 억제제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 암 유전자 억제제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
암 유전자 억제제 시장 : 경쟁 구도
암 유전자 억제제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bayer AG
Bristol-Myers Squibb Company
Novartis AG
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Mirati Therapeutics Inc.
AstraZeneca PLC
Incyte Corporation
Blueprint Medicines Corporation
Astex Pharmaceuticals Inc.
G1 Therapeutics Inc.
Nurix Therapeutics Inc.
GenFleet Therapeutics Co Ltd.
Relay Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
암 유전자 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
암 유전자 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
암 유전자 억제제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
An oncogene inhibitor is a type of therapeutic agent or drug developed to inhibit the function of oncogenes, which are genes capable of triggering cancer when they become overactive or mutated. These inhibitors specifically target the abnormal proteins that oncogenes produce, which are responsible for driving unregulated cell division and tumor growth. By impeding these proteins, oncogene inhibitors can help to reduce or halt the development of certain cancers.
Oncogene inhibitors are mainly available in two forms: oral and injectable. Oral medications are taken by mouth and typically come in forms such as pills, tablets, capsules, or liquid solutions. These are used across various drug categories, including biologics, small molecule drugs, and combination therapies. The key indications include breast cancer, ovarian cancer, lung cancer, pancreatic cancer, and others. These drugs are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and they are utilized by different end users such as hospitals, specialty clinics, and other healthcare facilities.
The oncogene inhibitor market research report is one of a series of new reports from The Business Research Company that provides oncogene inhibitor market statistics, including oncogene inhibitor industry global market size, regional shares, competitors with an oncogene inhibitor market share, oncogene inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the oncogene inhibitor industry. This oncogene inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oncogene inhibitor market size has grown strongly in recent years. It will grow from $39.68 billion in 2024 to $43.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period is due to factors such as increased research on resistance mechanisms, the expansion of targeted therapies, heightened research efforts for lung cancer treatment, rising investment in KRAS and MYC inhibitors, and boosted funding and grants.
The oncogene inhibitor market size is expected to see strong growth in the next few years. It will grow to $60.36 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period is due to increased healthcare investments, the emphasis on tumor-agnostic treatments, rising use of targeted therapies, supportive regulatory and reimbursement frameworks, and the advancement of personalized medicine and companion diagnostics. Key trends expected during this period include the emergence of next-generation KRAS inhibitors, AI-powered drug discovery platforms, integration of real-time liquid biopsy, modulation of the tumor microenvironment, and the development of targeted nanoparticle-based drug delivery systems.
An increase in the prevalence of cancer is expected to propel the growth of the oncogene inhibitor market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. It is increasing due to unhealthy lifestyles, as habits such as smoking, poor diet, lack of exercise, and alcohol use weaken the body and promote the growth of cancerous cells. Oncogene inhibitors help combat cancer by targeting and blocking specific genes that drive cancer cell growth, thereby slowing or stopping tumor development and progression. For instance, in July 2024, according to a report published by Cancer Research UK, a UK-based charity, the average annual number of new melanoma skin cancer cases in the UK is expected to increase from approximately 20,800 in 2023-2025 to around 26,500 in 2038-2040. Therefore, an increase in the prevalence of cancer is driving the growth of the oncogene inhibitor market.
Major companies operating in the oncogene inhibitor market are focusing on developing innovative treatment options, such as novel functional genomic approaches, to enhance the precision and efficacy of cancer treatments. Novel functional genomic approaches refer to advanced methodologies that integrate various genomic, transcriptomic, and epigenomic data to understand gene functions and their roles in diseases such as cancer. For instance, in May 2024, Delphia Therapeutics, a US-based biotechnology company, introduced a novel approach called activation lethality to exploit cancer's vulnerability to oncogene overactivation. Leading oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon have secured $67 million in funding to advance this strategy. Activation lethality targets the excessive activation of oncogenes, genes that, when mutated or highly expressed, can drive cancer development. Some cancer cells rely on this overactivation for survival, and by inducing lethal stress through targeted intervention, this approach selectively kills those cancer cells while sparing healthy ones.
In November 2023, Revolution Medicines Inc., a US-based biotech company, acquired EQRx for an undisclosed amount. Through this acquisition, EQRx benefits by aligning with a company that has a strong focus on developing RAS(ON) inhibitor drugs for RAS-driven cancers, potentially accelerating the development and commercialization of its oncology programs. Additionally, the acquisition offers EQRx greater access to resources, expertise, and infrastructure, enhancing its ability to advance innovative oncogene inhibitor therapies. EQRx Inc. is a US-based biotech company that offers oncogene inhibitors.
Major players in the oncogene inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Mirati Therapeutics Inc., AstraZeneca PLC, Incyte Corporation, Blueprint Medicines Corporation, Astex Pharmaceuticals Inc., G1 Therapeutics Inc., Nurix Therapeutics Inc., GenFleet Therapeutics Co Ltd., Relay Therapeutics Inc.
North America was the largest region in the oncogene inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncogene inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the oncogene inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oncogene inhibitor market consists of sales of imatinib, erlotinib, gefitinib, vemurafenib, dabrafenib, crizotinib, and ceritinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oncogene Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oncogene inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oncogene inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncogene inhibitor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Oral; Injection
2) By Drug Class: Small Molecule Drugs; Biologics; Combination Therapies
3) By Indication: Breast Cancer; Ovarian Cancer; Lung Cancer; Pancreas Cancer; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Oral Oncogene Inhibitors: Small Molecule Inhibitors; Targeted Therapy Pills; Tyrosine Kinase Inhibitors (TKIs)
2) By Injection Oncogene Inhibitors: Monoclonal Antibodies (mAbs); Peptide Receptor Radioligand Therapy (PRRT); Small Molecule Inhibitors (Injectable); Gene Therapy Injections
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Oncogene Inhibitor Market Characteristics
3. Oncogene Inhibitor Market Trends And Strategies
4. Oncogene Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Oncogene Inhibitor Growth Analysis And Strategic Analysis Framework
5.1. Global Oncogene Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oncogene Inhibitor Market Growth Rate Analysis
5.4. Global Oncogene Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oncogene Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oncogene Inhibitor Total Addressable Market (TAM)
6. Oncogene Inhibitor Market Segmentation
6.1. Global Oncogene Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injection
6.2. Global Oncogene Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Drugs
Biologics
Combination Therapies
6.3. Global Oncogene Inhibitor Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Ovarian Cancer
Lung Cancer
Pancreas Cancer
Other Indications
6.4. Global Oncogene Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Oncogene Inhibitor Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-Users
6.6. Global Oncogene Inhibitor Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Inhibitors
Targeted Therapy Pills
Tyrosine Kinase Inhibitors (TKIs)
6.7. Global Oncogene Inhibitor Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies (MAbs)
Peptide Receptor Radioligand Therapy (PRRT)
Small Molecule Inhibitors (Injectable)
Gene Therapy Injections
7. Oncogene Inhibitor Market Regional And Country Analysis
7.1. Global Oncogene Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oncogene Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
